CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Dr. Veillette is a Full Research Professor and Director of the Molecular Oncology Research Unit, Institut de recherches cliniques de Montréal (IRCM), Full Professor, Department of Medicine, University of Montréal, Adjunct Professor, Department of Experimental Medicine, McGill University, and the Executive Director at the Marathon of Hope Cancer Centres Network, The Terry Fox Research Institute.
CCTG Central Office 2025/2026 Holiday hours and closures
Normal office hours resume on January 5th, 2026 at 8:30 am EST
Shipment of Specimens for Banking + Kit Supply
The Canadian Cancer Trials Group is actively seeking Clinical Research Associate (CRA) representatives from our Canadian member sites to sit on the CRA Executive Committee.
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
NCI MyeloMATCH Presentations at ASH 2025
MyeloMATCH opened in mid-2024, and the first results from the trial are being presented at the 2025 ASH Annual Meeting (December 6-9, 2025; Orlando, FL). There will be an oral presentation and five posters at the meeting, please see the detailed information here >
MA34 (BIG 4-11): A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as AdjuvantTherapy in Patients with Operable HER2-Positive Primary Breast Cancer trial has permanently closed.
